Drug Profile


Alternative Names: 240563; Bosatria; Mepolizamab; Nucala; SB-240563

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; McMaster University
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Hypereosinophilic syndrome
  • Phase II Nasal polyps
  • No development reported Eosinophilic oesophagitis

Most Recent Events

  • 23 Mar 2017 GlaxoSmithKline plans a phase III trial for Nasal polyps (NCT03085797)
  • 06 Mar 2017 Adverse events and efficacy data from the phase IIIb MUSCA trial in Asthma released by GlaxoSmithKline
  • 01 Mar 2017 Phase-III clinical trials in Hypereosinophilic syndrome (Adjunctive treatment, In adolescents, In adults, In the elderly) in Germany (SC) (NCT02836496)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top